GTPase KRAS G12D mutant and/or G12V mutant inhibitors potentially useful for the treatment of cancer have been detailed in a Quanta Therapeutics Inc.

Suzhou Zion Pharma Technology Co. Ltd. has identified GTPase KRAS G12D or G13D mutant and/or KRAS inhibitors reported to be useful for the treatment of cancer.

More information: Emily K.W. Lo et al, DNA methylation memory of pancreatic acinar-ductal metaplasia transition state altering Kras-downstream PI3K and Rho GTPase signaling in the absence of Kras ...

as mutant Ras proteins that lack GTPase activity, which normally turns Ras off, were found in many types of human tumours. We now know that, depending on the cellular context, Ras can contribute ...